Embryo Editing Gets Green Light in U.K.

Researchers at the Francis Crick Institute in London will use CRISPR/Cas9 to modify genes in early human embryos.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, NINASESResearchers in the U.K. will soon use precision genome-editing on human embryos in an effort to probe the mysteries of early development. And they’ll do it with the blessing of government regulators. On Monday (February 1), the U.K.’s Human Fertilisation and Embryology Authority (HFEA) made the unprecedented step of approving a project involving the editing of genes in early human embryos.

Scientists in China made headlines last year when they announced their application of CRISPR/Cas9 to modify structurally deficient human zygotes. The April Protein & Cell paper reporting the findings set off alarm bells across the life science community, dividing researchers between those who thought the move was premature and ill-advised and those who warned of the dangers of stifling such research.

The UK researchers who will apply the technique to early human embryos, which will be destroyed after seven days of growth, are the first scientists to conduct such experiments with clearance from their government’s regulatory authorities. “China has guidelines, but it is often unclear exactly what they are until you've done it and stepped over an unclear boundary,” Robin Lovell-Badge, scientific adviser to the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies